Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies

Inflammatory Bowel Diseases

Volumn 18, Issue 10, 2012, Pages 1894-1899

  Mao, Ren ^a   Xiao, Ying Lian ^a   Gao, Xiang ^a   Chen, Bai Li ^a   He, Yao ^a   Yang, Li ^a   Hu, Pin Jin ^a   Chen, Min Hu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Crohn's disease; fecal calprotectin; Inflammatory bowel disease; ulcerative colitis

Indexed keywords

CALGRANULIN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); DIAGNOSTIC ACCURACY; ENTERITIS; HUMAN; META ANALYSIS (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RELAPSE; REMISSION; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE;

EID: 84861869143     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22861     Document Type: Article

References (31)

1. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007; 133: 412-422. (Pubitemid 47187355)
2. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991; 32: 174-178.
3. Saverymutti SH,. Clinical remission in Crohn's disease-assessment using faecal 111In granulocyte excretion. Digestion. 1986; 33: 74-79.
4. Nielsen OH, Vainer B, Madsen SM, et al. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol. 2000; 95: 359-367. (Pubitemid 30106162)
5. Vermeire S, Van Assche G, Rutgeerts P,. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006; 55: 426-431. (Pubitemid 43268284)
6. Gisbert JP, Gonzalez-Lama Y, Mate J,. Role of biological markers in inflammatory bowel disease. Gastroenterol Hepatol. 2007; 30: 117-129. (Pubitemid 46682851)
7. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis. 2010; 4: 7-27.
8. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007; 102: 803-813. (Pubitemid 46496634)
9. Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997; 58: 176-180. (Pubitemid 27163169)
10. Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008; 14: 40-46. (Pubitemid 351196867)
11. Gisbert JP, McNicholl AG,. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis. 2009; 41: 56-66.
12. Gisbert JP, Bermejo F, Perez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009; 15: 1190-1198.
13. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005; 54: 364-368. (Pubitemid 40299092)
14. D'Inca R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol. 2008; 103: 2007-2014.
15. Kallel L, Ayadi I, Matri S, et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol. 2010; 22: 340-345.
16. Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis. 2010; 4: 144-1452.
17. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000; 119: 15-22. (Pubitemid 30452574)
18. Pardi DS, Sandborn WJ,. Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? Gut. 2005; 54: 321-322. (Pubitemid 40299082)
19. Hanaway P, Roseth A,. Inflammatory biomarkers predict relapse in IBD. Gut. 2005; 54: 1346-1347. (Pubitemid 41192505)
20. Ho GT, Lee HM, Brydon G, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009; 104: 673-678.
21. Wagner M, Peterson CG, Ridefelt P, et al. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol. 2008; 14: 5584-5589.
22. Diamanti A, Colistro F, Basso MS, et al. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases. Inflamm Bowel Dis. 2008; 14: 1229-1135.
23. Walkiewicz D, Werlin SL, Fish D, et al. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 669-673. (Pubitemid 351742984)
24. Sipponen T, Kolho KL,. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol. 2010; 45: 872-877.
25. Whiting PF, Weswood ME, Rutjes AW, et al. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol. 2006; 6: 9.
26. Deville WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol. 2002; 2: 9.
27. van Rheenen PF, Van de Vijver E, Fidler V,. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010; 341: c3369.
28. Aadland E, Fagerhol MK,. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002; 14: 823-825. (Pubitemid 34913578)
29. Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992; 27: 793-798.
30. Deeks JJ,. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001; 323: 157-162. (Pubitemid 32678396)
31. Whiting P, Rutjes AW, Reitsma JB, et al. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med. 2004; 140: 189-202. (Pubitemid 38155650)